SMTI Sanara MedTech Inc.

Q3 2025 10-Q
Filed: Nov 12, 2025Period ending Sep 30, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR

Sanara MedTech Inc. (SMTI) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 12, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • New financial risk: CRG Term Loan amendment allows up to two additional borrowings totaling $12.25 million by Dec 31, 2025, increasing debt capacity
  • Most materially updated operational risk: Discontinuation of THP segment following persistent losses and failed investor interest, segment impairment of $31.2 million Q3 2025
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$26M

Net Income

-$30M

Gross Margin

92.9%

Operating Margin

31.8%

Net Margin

-115.6%

ROE

-494.6%

Total Assets

$71M

Source: XBRL data from Sanara MedTech Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Sanara MedTech Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.